Nykode Therapeutics AS (STU:5VB) Accumulated Depreciation: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:5VB Nykode Therapeutics AS STU:5VB
38 GF Score
Price €0.35
GF Value €0.55
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Accumulated Depreciation?

Nykode Therapeutics AS STU:5VB -0.57% 38 Accumulated Depreciation is €0.00 Mil as of Jun. 2026. GuruFocus rates STU:5VB with a GF Score™ of 38/100 and a GF Value™ of €0.55 (Possible Value Trap). The stock has 3 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Nykode Therapeutics AS's quarterly accumulated depreciation declined from Dec. 2025 (€-8.01 Mil) to Mar. 2026 (€0.00 Mil) but then stayed the same from Mar. 2026 (€0.00 Mil) to Jun. 2026 (€0.00 Mil).

Nykode Therapeutics AS's annual accumulated depreciation increased from Dec. 2023 (€-4.71 Mil) to Dec. 2024 (€-7.04 Mil) and increased from Dec. 2024 (€-7.04 Mil) to Dec. 2025 (€-8.01 Mil).

Nykode Therapeutics AS Accumulated Depreciation Related Terms

Nykode Therapeutics AS Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Accumulated Depreciation Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only -1.08 -2.84 -4.71 -7.04 -8.01

Nykode Therapeutics AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -8.01 0.00 0.00
STU:5VB
38GF Score
Nykode Therapeutics AS STU:5VB
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of €0.00 Mil mean?
Nykode Therapeutics AS (STU:5VB) has a Accumulated Depreciation of €0.00 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Accumulated Depreciation too high?
Nykode Therapeutics AS's current Accumulated Depreciation is €0.00 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Accumulated Depreciation compare to VRTX and REGN?
Nykode Therapeutics AS's Accumulated Depreciation of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Accumulated Depreciation is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (STU:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.55, compared to a current price of €0.35 — trading 36.2% below its estimated fair value. The current Accumulated Depreciation is €0.00 Mil. Nykode Therapeutics AS's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Nykode Therapeutics AS (STU:5VB), the current Accumulated Depreciation is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (STU:5VB) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of €0.35 is trading 36.2% below its estimated GF Value™ of €0.55. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for STU:5VB:

  • Accumulated Depreciation: €0.00 Mil
  • GF Value™: €0.55 vs. price of €0.35 (36.2% below fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the STU:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
38GF Score

Get the complete analysis for STU:5VB

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.35
Price
€0.55
GF Value